Premium
Lipid effects of celiprolol, a new cardioselective β‐blocker, versus propranolol
Author(s) -
Sirtori Cesare R,
Johnson Bruce,
Vaccarino Viola,
Montanari Guido,
Cremoncini Mario,
Gianfranceschi Gemma,
Sirtori Marina,
Dujovne Carlos A
Publication year - 1989
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1989.82
Subject(s) - celiprolol , propranolol , hyperlipidemia , endocrinology , medicine , cholesterol , triglyceride , high density lipoprotein , lipoprotein , very low density lipoprotein , chemistry , heart rate , blood pressure , diabetes mellitus
The metabolic effects of celiprolol, a new β‐adrenoceptor blocking agent with intrinsic sympathomimetic activity and α 2 ‐blocking properties, were evaluated in a series of patients with hypertension, both with and without hyperlipidemia. Propranolol was tested as the reference drug in a randomized double‐blind trial. Of the 35 patients of both sexes who completed the study, 17 were hyperlipidemic (low‐density lipoprotein cholesterol ≥170 mg/dl) and 18 were normolipidemic. Both drugs exerted a similar hypotensive effect after gradual dose adjustment; however, propranolol reduced heart rate to a higher extent (‐20.5%) than celiprolol (‐7.7%). Propranolol determined a significant rise of total and very low‐density lipoprotein (VLDL) associated triglyceridemia, whereas high‐density lipoprotein cholesterol (HDL cholesterol) levels and the total cholesterol/HDL cholesterol ratios were significantly depressed, particularly in hyperlipidemic patients. Celiprolol, in contrast, slightly decreased triglyceridemia (significantly in the hyperlipidemic group at week 12) and caused a 5% increase of the HDL cholesterol levels. The total cholesterol/HDL cholesterol ratio was reduced by celiprolol at week 16 in both hyperlipidemic and normolipidemic patients. The effects of the two β‐adrenoceptor blockers on HDL cholesterol and triglyceride levels differed significantly after 12 and 16 weeks of treatment, which confirm the divergent metabolic effects of the two agents. Clinical Pharmacology and Therapeutics (1989) 45 , 617–626; doi: 10.1038/clpt.1989.82